Patient authorization to access certain investigational sun protection products

Texas Senate Bill 670 (SB670) allows patients to use certain sun protection products that are still under investigation and have not yet received full approval from the U.S. Food and Drug Administration (FDA). Specifically, the bill permits access to sun protection products containing ingredients that have successfully completed phase one of clinical trials but are not yet approved for general use. To be eligible, a patient must consult with their physician, who must determine that standard FDA-approved sun protection products are less effective for the patient's needs. The bill emphasizes patient autonomy and informed consent, enabling individuals to make decisions about their health in consultation with their healthcare providers.

Supporters of SB670 argue that the bill empowers patients by providing them with more options for sun protection, especially when existing FDA-approved products are insufficient. They highlight the bill's focus on patient autonomy and informed consent, allowing individuals to make proactive decisions about their health in collaboration with their physicians. The bipartisan sponsorship and passage of the bill suggest broad legislative support for expanding patient access to investigational treatments.

Critics of SB670 express concerns about the safety and efficacy of allowing access to sun protection products that have not completed the full FDA approval process. They worry that patients might be exposed to products with unknown long-term effects or insufficient evidence of effectiveness. Additionally, there are apprehensions about the potential for reduced regulatory oversight and the precedent it sets for accessing other investigational products without comprehensive approval.